Treatment update of painful peripheral diabetic neuropathy. Diabetic neuropathy committe 2015. Argentine Society of Diabetes
DOI:
https://doi.org/10.47196/diab.v50i1.77Keywords:
diabetic neuropathy, hyperalgesia, pathogenic treatment, symptomatic treatmentAbstract
Diabetes is a chronic and progressive disease associated with potentially disabling complications. Among them, diabetic neuropathy is probably the most frequent symptomatic manifestation, having an important social and economic impact. Painful somatic neuropathy and autonomic neuropathy treatment have been a challenge for years. New medical approaches that relief pain are now available and give hope to diabetic patients.
References
Lee JH, Cox DJ, Mook DG, McCarty RC. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. Pain. 1990; 40(1):105-107.
Moss SE, et ál. WESDR. Arch. Intern. Med. 1992; 152: 610-616.
DCCT Research Group. N. Engl. J. of Med. 1993; 329: 977-986.
Ohkubo Y, et ál. Diabetes Res. Clin. Pract. 1995; 28: 103-117.
Turner RC, Holman RR, Cull CA, et ál. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998: 352; (9131): 837-853.
Tammy JL, Blake CR, Vincent S, et ál. Treating diabetic peripheral neuropathic pain. Saint Louis University Family Medicine Residency Program, Belleville, Illinois. American Family Physician. 2010; 82, (2): 151-158.
Brownlee M. Metabolism. 2000; 49 (2 sppl 1): 9-13.
Greene DA, et ál. N. Engl. J. Med. 1987; 316:599-606.
Javed S, Malik R. Therapeutic Advances in Chronic Disease 2015; 6(1): 15-28.
Albers JW, Herman WH, PopBusui R, et ál. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010; 33, (5): 1090-1096.
PopBusui R, Low PA, Waberski BH, et ál. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Circulation 2009; 119, (22): 2886-2893.
Patel A, MacMahon S, Chalmers J, et ál. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N. Engl. J. Med. 2008; 358 (24): 2560-2572.
Duckworth W, Abraira C, Moritz T, et ál. Glucose control and vascular complications in veterans type 2 diabetes. VADT Investigators. N. Eng. J. Med 2009; 360 (2): 129-139.
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et ál. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: metaanalysis of randomised controlled trials. BMJ 2011; 343: d4169.
Callaghan B, Little A, Feldman E, et ál. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst. Rev 6: CD007543.
Sociedad Argentina de Diabetes. Guías de práctica clínica para el manejo de la diabetes tipo 1. Buenos Aires, 2006.
Ziegler D. Treatment of diabetic neuropathy and neuropathy pain: How far have we come? Diabetes Care 31 (Suppl. 2): S255-261, 2008.
Fioretto P, Steffes M, Sutherland D, et ál. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. Med. 1998; 339: 69-75.
Vincent A, Callaghan B, Smith A, et ál. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat. Rev. Neurol. 2011; 7: 573-583.
Ametov AS, Barinov A, Dyck PJ, et ál. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26: 770-776.
Ruhnau KJ, Meissner HP, Finn R, et ál. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med. 1999; 16 (12): 1040-1043.
Ziegler D, Hanefeld M, Ruhnau KJ, et ál. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38:1425-1433.
Reljanovic M, Reichel G, Rett K, et ál. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy free radic. Res. 1999 31 (3): 171-179.
Ziegler D, et ál. Oral treatment with alfa lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006, 29:2365-70.
Ziegler D, et ál. Antioxidant treatment with alpha lipoic acid in diabetic polyneuropathy. A 4-yearsrandomiseddoublé-blinded trial (NATHAN 1 Study). Diabetologia 2007, 50; Suppl 1, S63.
Ziegler D, Nowak H, Kempler P, et ál. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 21: 114-121.
Ziegler D, et ál. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32:1479-1484.
Ziegler D. Current concepts in the management of diabetic polyneuropathy. Current Diabetes Reviews 2011; 7: 208 220.
Hammes H, Du X, Edelstein D, et ál. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 2003 9: 294-299.
Stracke H, Gaus W, Achenbach U, et ál. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a randomised, double blind, placebo-controlled Clinical Study. Exp. Clin. Endocrinol. Diabetes 2008; 116: 600-605.
Boulton A, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy. Diabetes Metab. Res. Rev. 2013; 29: 327-333.
Goto Y, Hotta N, Shigeta Y, et ál. Effects of aldose reductase inhibitor, epalrestat, on diabetic neuropathy, clínic benefits and indications for the drug assessed from the results of a placebo-controlled double blind study. Biomed. Pharmacother 1995; 49: 269-277.
Hotta N, Akanuma Y, Kawamori R, et ál. Long term clinical effects of epalrestat, and aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 2006; 29:1538-1544.
Keen H, Payan J, Allawi J, et ál. Treatment of diabetic neuropathy with linolenic acid. Diabetes Care 1993;16:8-15.
Scafidi S, Fiskum G, Lindauer SL, et ál. Metabolism of acetil-carnitine for energy and neurotransmiter synthesis in the immature rat brain. J. Neurochem. 2010; 114: 820-831.
Evans JD, Jacobs TF, Evans EW. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann. Pharmacoter. 2008; 42: 1686-1691.
Finnerup NB, Otto M, McQuay HJ, et ál. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305.
Max MB, Lynch SA, Muir J, et ál. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl. J. Med. 1992; 326: 1250-1256.
Ulugol A, Karadag HC, Tamer M. Involvement of adenosine in the antiallody nice effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci. Lett. 2002; 328: 129-132.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 2007; 4: CD005454.
US Food and Drug Administration. Medication guide: Pamelor, http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088671.pdf (accessed 27 April 2014).
Moulin DE, Clark AJ, Gilron I, et ál. Pharmacological management of chronic neuropathic pain-consensus statementand guidelines from the Canadian Pain Society. Pain Res. Manag. 2007; 12: 13-21.
Gilron I, Bailey JM, Tu D, et ál. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374: 1252-1261.
Morello CM, Leckband SG, Stoner CP, et ál. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. 1999; 159: 1931-1937.
Sima AA, Calvani M, Mehra M, et ál. Acetyl-l-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28: 89-94.
National Institute for Health and Clinical Excellence. Neuropathic pain-pharmacological management: the farmacological management of neuropathic pain in adults in non-speciallist settings. 2013.
Vinik A, et ál. Evidence based management of diabetes. 2012. Chapter 19, 348-349.
Vinik A, Caselli C, Nevoret ML. Endotext. Diabetic neuropathy. Last Update: august 2015.
Kajdasz DK, Iyengar S, Desaiah D, et ál. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin. Ther. 2007; 29 Suppl: 2536-2546.
Wernicke JF, Pritchett YL, D’Souza DN, et ál. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411-1420.
Quilici S, Chancellor J, Lothgren M, et ál. Meta-analysis of duloxetine vs pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology 2009; 9: 6. doi: 10.1186/1471-2377-9-6.
Montfort EG, Witte AP, Ward K. Neuropathic pain: a review of diabetic neuropathy. US Pharm 2010; 35: HS8-HS15.
Hardy T, Sachson R, Shen S, et ál. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30:21-26.
Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont ) 2008; 5: 16-19.
Effexor XR (venlafaxine extended release) prescribing information. Philadelphia,Pennsylvania: Wyeth Pharmaceuticals, Inc.; February 2015.
La Roche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291: 605-14. 128,132.
Lesser H, Sharma U, LaMoreaux L, et ál. Pregabalin relieves symptoms of painfuldiabetic neuropathy: a randomized controlled trial. Neurology 2004; 63:2104-10.
Richter RW, Portenoy R, Sharma U, et ál. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain 2005; 6: 253-60.
Moulin DE, Boulanger A, Clark AJ, et ál. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res. Manag. 2014; 19(6):328-335.
Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31:1448-54.
Backonja M, Beydoun A, Edwards KR, et ál. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA.1998;280:1831-1836.
DeToledo JC, Toledo C, De Cerce J, et ál. Changes in body weight with chronic, high-dose gabapentin therapy. Ther. Drug Monit. 1997;19:394-396.
Gilron I, Bailey JM, Tu D, et ál. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 2005; 352:1324-1334.
Schreiber AK, Nones CF, Reis RC, et ál. Diabetic neuropathic pain: Physiopathology and treatment. World J. Diabetes 2015 April 15; 6(3): 432-444.
Kalso E. Sodium channel blockers in neuropathic pain. Curr. Pharm. Des. 2005; 11:3005-3011.
Vinik AI. Diabetic neuropathies: endpoints in clinical research studies. In: Le Roith D, Vinik AI, editors. Controversies in treating diabetes: clinical and research aspects (Contemporary Endocrinology). Totowa, NJ: Human Press; 2008:135-156.
Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst. Rev. 2006;(3):CD006146.
Watson CP, Moulin D, Watt-Watson J, et ál. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105(1-2):71-78.
Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J. Pain Symptom Manage 2000; 19:S21-S25.
Schwartz S, Etropolski M, Shapiro DY, et ál. Safety and efficacy of tapentadol in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr. Med. Res. Opin. 2011;27:151-162.
Harati Y, Gooch C, Swenson M, et ál. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-1846.
Cummins TR. Setting up for the block: the mechanism underlying lidocaine’s use-dependent inhibition of sodium channels. J. Physiol. 2007; 582 (Pt 1): 11.
Rosenberg CJ, Watson JC. Treatment of painful diabetic peripheral neuropathy. Prosthetics and Orthotics International 2015, Vol. 39 (1) 17- 28.
Cohen K, Shinkazh N, Frank J, et ál. Pharmacological treatment of diabetic peripheral neuropathy. P&T®, June 2015, Vol. 40 Nº 6.
American Academy of Neurology. AAN summary of evidence-based guidelines for clinicians: treatment of painful diabetic neuropathy. 2011. Availableat: https://www.aan.com/Guidelines/home/GetGuidelineContent/480. Accessed March 13, 2015.
Montfort EG, Witte AP, Ward K. Neuropathic pain: a review of diabetic neuropathy. US Pharm 2010; 35:HS8-HS15.
Flores MP, de Castro APCR, Nascimento JDS. Topical analgesics. Rev. Bras. Anestesiol. 2012; 62:244-252.
Ho K, Huh BK, White WD, et ál. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin. J. Pain 2008;24:51-55.
Lynch ME, Clark AJ, Sawynok J, et ál. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology 2005; 103:140-146.
Estebe JP, Myers RR. Amitriptyline neurotoxicity: dose-related pathology after topical application to rat sciatic nerve. Anesthesiology 2004; 100:1519-1525.
Piovesan EJ, Teive HG, Kowacs PA, et ál. An open study of botulinum. A toxin treatment of trigeminal neuralgia. Neurology 2005; 65:1306-1308.
Tsai CP, Liu CY, Lin KP, et ál. Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience. Clin. Drug Investig. 2006; 26:511-515.
Pittler MH, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin. J. Pain 2008; 24:731-733.
Tesfaye S. Painful diabetic neuropathy. Aetiology and non pharmacological treatment. In: Veves A, editor. Clinical management of diabetic neuropathy. Totowa (NJ): Human Press; 1998. p. 369-86.
Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374:1252-1261.
Tesfaye S, Vileikyte L, Rayman G, et ál. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab. Res. Rev. 2011;27:629-638.
Lexi-Comp [online reference library]. Hudson, Ohio: American Pharmaceu-tical Association; 2009. Updated daily. http://online.lexi.com (subscription required). Accessed October 27, 2009.
Boyer EW, Shannon M. The serotonin syndrome [published corrections appear in N Engl J Med. 2009;361(17):1714 and N Engl J Med. 2007; 356:(23):2437]. N. Engl. J. Med. 2005;352(11):1112-1120.
Gore M, Sadosky A, Leslie D, et ál. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the U.K. and Germany Mediplus databases. Pain Pract. 2008; 8(4):253-262.
Burke JP, Sanchez RJ, Joshi AV, et ál. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine. Pain Pract. 2012; 12:209-218.
De Salas-Cansado M, Perez C, Saldana MT, et ál. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings. Prim Care Diabetes. Epub May 15, 2012.
Bellows BK, Dahal A, Jiao T, Biskupiak J. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J. Pain Palliat Care Pharmacother. 2012; 26:153-164.
Tesfaye S, Vileikyte L, Rayman G, et ál. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab. Res. Rev. 2011; 27:629-638.
Vinik A. The approach to the management of the patient with neuropathic pain. J. Clin. Endocrinol. Metab. 2010; 95:4802-4811.
Bril V, England J, Franklin GM, et al. Evidence based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76:1758-1765.
Argoff C, Backonja M, Belgrade M, et ál. Consensus guidelines: treatment and planning options: diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006; 81 (suppl):S12-S25.
Tan T, Barry P, Reken S, et ál. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010; 340:c1079.
Javed S, Petropoulos LN, Alam U, et ál. Treatment of painful diabetic neuropathy. Ther. Adv. Chronic. Dis. 2015, Vol. 6 (1) 15-28.
Summary of evidence-based Guideline for Clinicians treatment of painful diabetic neuropathy. American Academy of Neurology (AAN) guideline update regarding pharmacologic and nonpharmacologic treatment of painful diabetic neuropathy (PDN) 2011.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
